A Research Opportunity Announcement (ROA) is a public document that announces the availability of an Other Transaction (OT). It provides the initiative’s purpose, type of award, instructions on how to apply, due date for proposals or applications, and research opportunity number.
Information about Other Transactions can be found on the NIH Grants & Funding website.
File
| Title | OTA Number | Purpose | OTA Category | Contact |
|---|---|---|---|---|
| StrokeNet Thrombectomy Platform (STEP) – Domain Clinical trials to be conducted in STEP: Stage 2 Protocol Application (OT2) | OTA-24-010 | The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Protocol Applications for clinical trials that will address the indication expansion of current endovascular therapy (EVT) criteria, concomitant medical therapies added to EVT, novel EVT devices, and systems of care for EVT,to be conducted within the StrokeNet Thrombectomy Platform (STEP) within the NIH StrokeNet network. | STEP | Scott Janis, PhD |
| StrokeNet Thrombectomy Platform (STEP) – Domain Clinical trials to be conducted in STEP: Stage 1 Preliminary Application (OT2) | OTA-24-009 | The purpose of this research opportunity announcement (ROA) is to invite Stage 1 Preliminary Applications for clinical trials that will address the indication expansion of current endovascular therapy (EVT) criteria, concomitant medical therapies added to EVT, novel EVT devices, and(STEP) within the NIH StrokeNet network. | STEP | Scott Janis, PhD |
| Ultra-rare Gene-based Therapy (URGenT) Clinical Trials Conducted within NeuroNEXT: Stage 1 Preliminary Application (OT2) | OTA-24-011 | The purpose of this research opportunity announcement (ROA) is to invite Stage 1 Preliminary Applications for clinical trials of gene-based and gene-targeted therapies for ultra-rare neurological diseases, to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). | URGent | Sophie (Hyun Joo) Cho, MD |
| Ultra-rare Gene-based Therapy (URGenT) Clinical Trials Conducted within NeuroNEXT: Stage 2 Protocol Application (OT2) | OTA-24-012 | The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Protocol Applications for clinical trials of gene-based and gene-targeted therapies for ultra-rare neurological diseases, to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). | URGent | Sophie (Hyun Joo) Cho, MD |
| OTA-24-013: NeuroNEXT Clinical Trials: Stage 1 Preliminary Application (OT2) | OTA-24-013 | The purpose of this research opportunity announcement (ROA) is to invite applicants to submit Stage 1 Preliminary Applications of assets proposed for exploratory clinical trials or biomarker studies focused on neurological diseases to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). | NeuroNext | Sophie (Hyun Joo) Cho, MD |
| OTA-24-014: NeuroNEXT Clinical Trials: Stage 2 Protocol Application (OT2) | OTA-24-014 | The purpose of this research opportunity announcement (ROA) is to invite applicants to submit Stage 2 Protocol Applications for exploratory clinical trials or biomarker studies focused on neurological diseases to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). | NeuroNext | Sophie (Hyun Joo) Cho, MD |